B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Report

Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size, Status and Forecast 2014-2026

  • POSTDATE：Mar 20, 2020
  • PAGES：212
  • REPORT CODE：GMM514356
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The B-Cell Maturation Antigen(BCMA) Targeted Therapies market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 4.7% during the forecast period. Focusing on the Europe market, this report analyzes the specific consumption structure, such as types and end users. In order to present the status of the circulation of this product in different Europe countries, this report covers top export and import countries to confirm the potential markets. Leading countries such as Germany, UK, France, Italy, Spain, Poland, Russia, Switzerland, Turkey, Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden), Benelux (Belgium, Netherlands, and Luxembourg), Baltic States (Estonia, Latvia, and Lithuania) and other countries, the market status and consumption potential of these countries are covered in the research, providing valuable opinions of strategic adjustments for existing groups and new entrants.

    The Snapshot of Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Segmentations:

    By Player:

    • Credit Suisse Securities

    • Malin Corporation

    • Sutro Biopharma

    • Juno Therapeutics

    • Deerfield Partners

    • Onyx Pharmaceuticals

    • Eureka Therapeutics

    • Transposagen Biopharmaceuticals

    • Dana-Farber Cancer Institute

    • Five Prime Therapeutics

    • firstVentury Equity

    By Type:

    • Bispecific Antibodies

    • Antibody Drug Conjugates

    • Chimeric Antigen Receptor T-Cells

    By End-User:

    • Liver Cancer

    • Respiratory Cancer

    • Brain Cancer

    • Others

    By Region:

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Poland

    • Russia

    • Switzerland

    • Turkey

    • Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden)

      • Denmark

      • Finland

      • Norway

      • Sweden

      • Iceland

    • Benelux (Belgium, Netherlands, and Luxembourg)

      • Belgium

      • Netherlands

      • Luxembourg

    • Baltic States (Estonia, Latvia, and Lithuania)

      • Estonia

      • Latvia

      • Lithuania

  • Table of Contents

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of B-Cell Maturation Antigen(BCMA) Targeted Therapies Market

    • 1.3 Market Segment by Type

    • 1.3.1 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate of Bispecific Antibodies from 2014 to 2026

    • 1.3.2 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate of Antibody Drug Conjugates from 2014 to 2026

    • 1.3.3 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate of Chimeric Antigen Receptor T-Cells from 2014 to 2026

    • 1.4 Market Segment by Application

    • 1.4.1 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate of Liver Cancer from 2014 to 2026

    • 1.4.2 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate of Respiratory Cancer from 2014 to 2026

    • 1.4.3 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate of Brain Cancer from 2014 to 2026

    • 1.4.4 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate of Others from 2014 to 2026

    • 1.5 Market Segment by Regions

      • 1.5.1 Germany B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 UK B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 France B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Italy B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Spain B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Poland B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Russia B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Switzerland B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate from 2014 to 2026

      • 1.5.9 Turkey B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate from 2014 to 2026

      • 1.5.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate from 2014 to 2026

      • 1.5.11 Benelux (Belgium, Netherlands, and Luxembourg) B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate from 2014 to 2026

      • 1.5.12 Baltic States (Estonia, Latvia, and Lithuania) B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate from 2014 to 2026

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    3 Segmentation of B-Cell Maturation Antigen(BCMA) Targeted Therapies Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Venders

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of B-Cell Maturation Antigen(BCMA) Targeted Therapies by Major Types

      • 3.4.1 Market Size and Growth Rate of Bispecific Antibodies

      • 3.4.2 Market Size and Growth Rate of Antibody Drug Conjugates

      • 3.4.3 Market Size and Growth Rate of Chimeric Antigen Receptor T-Cells

    4 Segmentation of B-Cell Maturation Antigen(BCMA) Targeted Therapies Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of B-Cell Maturation Antigen(BCMA) Targeted Therapies by Major End-Users

      • 4.4.1 Market Size and Growth Rate of B-Cell Maturation Antigen(BCMA) Targeted Therapies for Liver Cancer

      • 4.4.2 Market Size and Growth Rate of B-Cell Maturation Antigen(BCMA) Targeted Therapies for Respiratory Cancer

      • 4.4.3 Market Size and Growth Rate of B-Cell Maturation Antigen(BCMA) Targeted Therapies for Brain Cancer

      • 4.4.4 Market Size and Growth Rate of B-Cell Maturation Antigen(BCMA) Targeted Therapies for Others

    5 Market Analysis by Major Regions

    • 5.1 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Production Analysis by Top Regions

    • 5.2 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption Analysis by Top Regions

    • 5.3 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Production, Import, Consumption and Export Analysis by Regions

      • 5.3.1 Germany B-Cell Maturation Antigen(BCMA) Targeted Therapies Production, Import, Consumption and Export Analysis

      • 5.3.2 UK B-Cell Maturation Antigen(BCMA) Targeted Therapies Production, Import, Consumption and Export Analysis

      • 5.3.3 France B-Cell Maturation Antigen(BCMA) Targeted Therapies Production, Import, Consumption and Export Analysis

      • 5.3.4 Italy B-Cell Maturation Antigen(BCMA) Targeted Therapies Production, Import, Consumption and Export Analysis

      • 5.3.5 Spain B-Cell Maturation Antigen(BCMA) Targeted Therapies Production, Import, Consumption and Export Analysis

      • 5.3.6 Poland B-Cell Maturation Antigen(BCMA) Targeted Therapies Production, Import, Consumption and Export Analysis

      • 5.3.7 Russia B-Cell Maturation Antigen(BCMA) Targeted Therapies Production, Import, Consumption and Export Analysis

      • 5.3.8 Switzerland B-Cell Maturation Antigen(BCMA) Targeted Therapies Production, Import, Consumption and Export Analysis

      • 5.3.9 Turkey B-Cell Maturation Antigen(BCMA) Targeted Therapies Production, Import, Consumption and Export Analysis

      • 5.3.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) B-Cell Maturation Antigen(BCMA) Targeted Therapies Production, Import, Consumption and Export Analysis

      • 5.3.11 Benelux (Belgium, Netherlands, and Luxembourg) B-Cell Maturation Antigen(BCMA) Targeted Therapies Production, Import, Consumption and Export Analysis

      • 5.3.12 Baltic States (Estonia, Latvia, and Lithuania) B-Cell Maturation Antigen(BCMA) Targeted Therapies Production, Import, Consumption and Export Analysis

    6 Product Circulation of B-Cell Maturation Antigen(BCMA) Targeted Therapies Market among Top Countries

    • 6.1 Top 5 Export Countries in B-Cell Maturation Antigen(BCMA) Targeted Therapies Market from 2014 to 2019

      • 6.1.1 Top 5 Export Countries’ Export Value Analysis in B-Cell Maturation Antigen(BCMA) Targeted Therapies Market from 2014 to 2019

      • 6.1.2 Top 5 Export Countries’ Export Volume Analysis in B-Cell Maturation Antigen(BCMA) Targeted Therapies Market from 2014 to 2019

    • 6.2 Top 5 Import Countries in B-Cell Maturation Antigen(BCMA) Targeted Therapies Market from 2014 to 2019

      • 6.2.1 Top 5 Import Countries’ Import Value Analysis in B-Cell Maturation Antigen(BCMA) Targeted Therapies Market from 2014 to 2019

      • 6.2.2 Top 5 Import Countries’ Import Volume Analysis in B-Cell Maturation Antigen(BCMA) Targeted Therapies Market from 2014 to 2019

    • 6.3 Emerging Top 3 Export Countries Analysis

    • 6.4 Emerging Top 3 Import Countries Analysis

    7. Germany B-Cell Maturation Antigen(BCMA) Targeted Therapies Landscape Analysis

    • 7.1 Germany B-Cell Maturation Antigen(BCMA) Targeted Therapies Landscape Analysis by Major Types

    • 7.2 Germany B-Cell Maturation Antigen(BCMA) Targeted Therapies Landscape Analysis by Major End-Users

    8. UK B-Cell Maturation Antigen(BCMA) Targeted Therapies Landscape Analysis

    • 8.1 UK B-Cell Maturation Antigen(BCMA) Targeted Therapies Landscape Analysis by Major Types

    • 8.2 UK B-Cell Maturation Antigen(BCMA) Targeted Therapies Landscape Analysis by Major End-Users

    9. France B-Cell Maturation Antigen(BCMA) Targeted Therapies Landscape Analysis

    • 9.1 France B-Cell Maturation Antigen(BCMA) Targeted Therapies Landscape Analysis by Major Types

    • 9.2 France B-Cell Maturation Antigen(BCMA) Targeted Therapies Landscape Analysis by Major End-Users

    10. Italy B-Cell Maturation Antigen(BCMA) Targeted Therapies Landscape Analysis

    • 10.1 Italy B-Cell Maturation Antigen(BCMA) Targeted Therapies Landscape Analysis by Major Types

    • 10.2 Italy B-Cell Maturation Antigen(BCMA) Targeted Therapies Landscape Analysis by Major End-Users

    11. Spain B-Cell Maturation Antigen(BCMA) Targeted Therapies Landscape Analysis

    • 11.1 Spain B-Cell Maturation Antigen(BCMA) Targeted Therapies Landscape Analysis by Major Types

    • 11.2 Spain B-Cell Maturation Antigen(BCMA) Targeted Therapies Landscape Analysis by Major End-Users

    12. Poland B-Cell Maturation Antigen(BCMA) Targeted Therapies Landscape Analysis

    • 12.1 Poland B-Cell Maturation Antigen(BCMA) Targeted Therapies Landscape Analysis by Major Types

    • 12.2 Poland B-Cell Maturation Antigen(BCMA) Targeted Therapies Landscape Analysis by Major End-Users

    13. Russia B-Cell Maturation Antigen(BCMA) Targeted Therapies Landscape Analysis

    • 13.1 Russia B-Cell Maturation Antigen(BCMA) Targeted Therapies Landscape Analysis by Major Types

    • 13.2 Russia B-Cell Maturation Antigen(BCMA) Targeted Therapies Landscape Analysis by Major End-Users

    14. Switzerland B-Cell Maturation Antigen(BCMA) Targeted Therapies Landscape Analysis

    • 14.1 Switzerland B-Cell Maturation Antigen(BCMA) Targeted Therapies Landscape Analysis by Major Types

    • 14.2 Switzerland B-Cell Maturation Antigen(BCMA) Targeted Therapies Landscape Analysis by Major End-Users

    15. Turkey B-Cell Maturation Antigen(BCMA) Targeted Therapies Landscape Analysis

    • 15.1 Turkey B-Cell Maturation Antigen(BCMA) Targeted Therapies Landscape Analysis by Major Types

    • 15.2 Turkey B-Cell Maturation Antigen(BCMA) Targeted Therapies Landscape Analysis by Major End-Users

    16. Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) B-Cell Maturation Antigen(BCMA) Targeted Therapies Landscape Analysis

    • 16.1 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) B-Cell Maturation Antigen(BCMA) Targeted Therapies Landscape Analysis by Major Types

    • 16.2 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) B-Cell Maturation Antigen(BCMA) Targeted Therapies Landscape Analysis by Major End-Users

    • 16.3 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) B-Cell Maturation Antigen(BCMA) Targeted Therapies Landscape Analysis by Top Countries

      • 16.3.1 Denmark B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Volume and Growth Rate

      • 16.3.2 Finland B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Volume and Growth Rate

      • 16.3.3 Norway B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Volume and Growth Rate

      • 16.3.4 Sweden B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Volume and Growth Rate

      • 16.3.6 Iceland B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Volume and Growth Rate

    17 Benelux (Belgium, Netherlands, and Luxembourg) B-Cell Maturation Antigen(BCMA) Targeted Therapies Landscape Analysis

    • 17.1 Benelux (Belgium, Netherlands, and Luxembourg) B-Cell Maturation Antigen(BCMA) Targeted Therapies Landscape Analysis by Major Types

    • 17.2 Benelux (Belgium, Netherlands, and Luxembourg) B-Cell Maturation Antigen(BCMA) Targeted Therapies Landscape Analysis by Major End-Users

    • 17.3 Benelux (Belgium, Netherlands, and Luxembourg) B-Cell Maturation Antigen(BCMA) Targeted Therapies Landscape Analysis by Top Countries

      • 17.3.1 Belgium B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Volume and Growth Rate

      • 17.3.2 Netherlands B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Volume and Growth Rate

      • 17.3.3 Luxembourg B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Volume and Growth Rate

    18 Baltic States (Estonia, Latvia, and Lithuania) B-Cell Maturation Antigen(BCMA) Targeted Therapies Landscape Analysis

    • 18.1 Baltic States (Estonia, Latvia, and Lithuania) B-Cell Maturation Antigen(BCMA) Targeted Therapies Landscape Analysis by Major Types

    • 18.2 Baltic States (Estonia, Latvia, and Lithuania) B-Cell Maturation Antigen(BCMA) Targeted Therapies Landscape Analysis by Major End-Users

    • 18.3 Baltic States (Estonia, Latvia, and Lithuania) B-Cell Maturation Antigen(BCMA) Targeted Therapies Landscape Analysis by Top Countries

      • 18.3.1 Estonia B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Volume and Growth Rate

      • 18.3.2 Latvia B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Volume and Growth Rate

      • 18.3.3 Lithuania B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Volume and Growth Rate

    19 Major Players Profiles

    • 19.1 Credit Suisse Securities

      • 19.1.1 Credit Suisse Securities Company Profile and Development Status

      • 19.1.2 Market Performance

      • 19.1.3 Product and Service Introduction

    • 19.2 Malin Corporation

      • 19.2.1 Malin Corporation Company Profile and Development Status

      • 19.2.2 Market Performance

      • 19.2.3 Product and Service Introduction

    • 19.3 Sutro Biopharma

      • 19.3.1 Sutro Biopharma Company Profile and Development Status

      • 19.3.2 Market Performance

      • 19.3.3 Product and Service Introduction

    • 19.4 Juno Therapeutics

      • 19.4.1 Juno Therapeutics Company Profile and Development Status

      • 19.4.2 Market Performance

      • 19.4.3 Product and Service Introduction

    • 19.5 Deerfield Partners

      • 19.5.1 Deerfield Partners Company Profile and Development Status

      • 19.5.2 Market Performance

      • 19.5.3 Product and Service Introduction

    • 19.6 Onyx Pharmaceuticals

      • 19.6.1 Onyx Pharmaceuticals Company Profile and Development Status

      • 19.6.2 Market Performance

      • 19.6.3 Product and Service Introduction

    • 19.7 Eureka Therapeutics

      • 19.7.1 Eureka Therapeutics Company Profile and Development Status

      • 19.7.2 Market Performance

      • 19.7.3 Product and Service Introduction

    • 19.8 Transposagen Biopharmaceuticals

      • 19.8.1 Transposagen Biopharmaceuticals Company Profile and Development Status

      • 19.8.2 Market Performance

      • 19.8.3 Product and Service Introduction

    • 19.9 Dana-Farber Cancer Institute

      • 19.9.1 Dana-Farber Cancer Institute Company Profile and Development Status

      • 19.9.2 Market Performance

      • 19.9.3 Product and Service Introduction

    • 19.10 Five Prime Therapeutics

      • 19.10.1 Five Prime Therapeutics Company Profile and Development Status

      • 19.10.2 Market Performance

      • 19.10.3 Product and Service Introduction

    • 19.11 firstVentury Equity

      • 19.11.1 firstVentury Equity Company Profile and Development Status

      • 19.11.2 Market Performance

      • 19.11.3 Product and Service Introduction

    The List of Tables and Figures (Totals 88 Figures and 131 Tables)

    • Figure Product Picture

    • Figure Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate of Bispecific Antibodies from 2014 to 2026

    • Figure Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate of Antibody Drug Conjugates from 2014 to 2026

    • Figure Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate of Chimeric Antigen Receptor T-Cells from 2014 to 2026

    • Figure Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate of Liver Cancer from 2014 to 2026

    • Figure Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate of Respiratory Cancer from 2014 to 2026

    • Figure Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate of Brain Cancer from 2014 to 2026

    • Figure Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate of Others from 2014 to 2026

    • Figure Germany B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate from 2014 to 2026

    • Figure UK B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate from 2014 to 2026

    • Figure France B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate from 2014 to 2026

    • Figure Italy B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate from 2014 to 2026

    • Figure Spain B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate from 2014 to 2026

    • Figure Poland B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate from 2014 to 2026

    • Figure Russia B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate from 2014 to 2026

    • Figure Switzerland B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate from 2014 to 2026

    • Figure Turkey B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate from 2014 to 2026

    • Figure Canada B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate from 2014 to 2026

    • Figure Mexico B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate from 2014 to 2026

    • Figure Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate from 2014 to 2026

    • Figure Denmark B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate from 2014 to 2026

    • Figure Finland B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate from 2014 to 2026

    • Figure Norway B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate from 2014 to 2026

    • Figure Sweden B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate from 2014 to 2026

    • Figure Iceland B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate from 2014 to 2026

    • Figure Benelux (Belgium, Netherlands, and Luxembourg) B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate from 2014 to 2026

    • Figure Belgium B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate from 2014 to 2026

    • Figure Netherlands B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate from 2014 to 2026

    • Figure Luxembourg B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate from 2014 to 2026

    • Figure Baltic States (Estonia, Latvia, and Lithuania) B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate from 2014 to 2026

    • Figure Estonia B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate from 2014 to 2026

    • Figure Latvia B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate from 2014 to 2026

    • Figure Lithuania B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of B-Cell Maturation Antigen(BCMA) Targeted Therapies Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of B-Cell Maturation Antigen(BCMA) Targeted Therapies

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of B-Cell Maturation Antigen(BCMA) Targeted Therapies by Different Types from 2014 to 2026

    • Table Consumption Share of B-Cell Maturation Antigen(BCMA) Targeted Therapies by Different Types from 2014 to 2026

    • Figure Market Size and Growth Rate of Bispecific Antibodies

    • Figure Market Size and Growth Rate of Antibody Drug Conjugates

    • Figure Market Size and Growth Rate of Chimeric Antigen Receptor T-Cells

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of B-Cell Maturation Antigen(BCMA) Targeted Therapies by Different End-Users from 2014 to 2026

    • Table Consumption Share of B-Cell Maturation Antigen(BCMA) Targeted Therapies by Different End-Users from 2014 to 2026

    • Figure Market Size and Growth Rate of Liver Cancer

    • Figure Market Size and Growth Rate of Respiratory Cancer

    • Figure Market Size and Growth Rate of Brain Cancer

    • Figure Market Size and Growth Rate of Others

    • Table Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Production by Major Regions

    • Table Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Production Share by Major Regions

    • Figure Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Production Share by Major Countries and Regions in 2014

    • Table Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption by Major Regions

    • Table Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption Share by Major Regions

    • Table Germany B-Cell Maturation Antigen(BCMA) Targeted Therapies Production, Import, Consumption and Export Analysis

    • Table UK B-Cell Maturation Antigen(BCMA) Targeted Therapies Production, Import, Consumption and Export Analysis

    • Table France B-Cell Maturation Antigen(BCMA) Targeted Therapies Production, Import, Consumption and Export Analysis

    • Table Italy B-Cell Maturation Antigen(BCMA) Targeted Therapies Production, Import, Consumption and Export Analysis

    • Table Spain B-Cell Maturation Antigen(BCMA) Targeted Therapies Production, Import, Consumption and Export Analysis

    • Table Poland B-Cell Maturation Antigen(BCMA) Targeted Therapies Production, Import, Consumption and Export Analysis

    • Table Russia B-Cell Maturation Antigen(BCMA) Targeted Therapies Production, Import, Consumption and Export Analysis

    • Table Switzerland B-Cell Maturation Antigen(BCMA) Targeted Therapies Production, Import, Consumption and Export Analysis

    • Table Turkey B-Cell Maturation Antigen(BCMA) Targeted Therapies Production, Import, Consumption and Export Analysis

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) B-Cell Maturation Antigen(BCMA) Targeted Therapies Production, Import, Consumption and Export Analysis

    • Table Benelux (Belgium, Netherlands, and Luxembourg) B-Cell Maturation Antigen(BCMA) Targeted Therapies Production, Import, Consumption and Export Analysis

    • Table Baltic States (Estonia, Latvia, and Lithuania) B-Cell Maturation Antigen(BCMA) Targeted Therapies Production, Import, Consumption and Export Analysis

    • Table Top 5 Export Countries' Export Value Analysis in B-Cell Maturation Antigen(BCMA) Targeted Therapies Market from 2014 to 2019

    • Table Top 5 Export Countries' Export Volume Analysis in B-Cell Maturation Antigen(BCMA) Targeted Therapies Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Value Analysis in B-Cell Maturation Antigen(BCMA) Targeted Therapies Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Volume Analysis in B-Cell Maturation Antigen(BCMA) Targeted Therapies Market from 2014 to 2019

    • Figure Emerging Top 3 Export Countries Analysis

    • Figure Emerging Top 3 Import Countries Analysis

    • Table Germany B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption by Types from 2014 to 2026

    • Table Germany B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption Share by Types from 2014 to 2026

    • Table Germany B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption by End-Users from 2014 to 2026

    • Table Germany B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption Share by End-Users from 2014 to 2026

    • Table UK B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption by Types from 2014 to 2026

    • Table UK B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption Share by Types from 2014 to 2026

    • Table UK B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption by End-Users from 2014 to 2026

    • Table UK B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption Share by End-Users from 2014 to 2026

    • Table France B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption by Types from 2014 to 2026

    • Table France B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption Share by Types from 2014 to 2026

    • Table France B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption by End-Users from 2014 to 2026

    • Table France B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption Share by End-Users from 2014 to 2026

    • Table Italy B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption by Types from 2014 to 2026

    • Table Italy B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption Share by Types from 2014 to 2026

    • Table Italy B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption by End-Users from 2014 to 2026

    • Table Italy B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption Share by End-Users from 2014 to 2026

    • Table Spain B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption by Types from 2014 to 2026

    • Table Spain B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption Share by Types from 2014 to 2026

    • Table Spain B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption by End-Users from 2014 to 2026

    • Table Spain B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption Share by End-Users from 2014 to 2026

    • Table Poland B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption by Types from 2014 to 2026

    • Table Poland B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption Share by Types from 2014 to 2026

    • Table Poland B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption by End-Users from 2014 to 2026

    • Table Poland B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption Share by End-Users from 2014 to 2026

    • Table Russia B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption by Types from 2014 to 2026

    • Table Russia B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption Share by Types from 2014 to 2026

    • Table Russia B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption by End-Users from 2014 to 2026

    • Table Russia B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption Share by End-Users from 2014 to 2026

    • Table Switzerland B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption by Types from 2014 to 2026

    • Table Switzerland B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption Share by Types from 2014 to 2026

    • Table Switzerland B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption by End-Users from 2014 to 2026

    • Table Switzerland B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption Share by End-Users from 2014 to 2026

    • Table Turkey B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption by Types from 2014 to 2026

    • Table Turkey B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption Share by Types from 2014 to 2026

    • Table Turkey B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption by End-Users from 2014 to 2026

    • Table Turkey B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption Share by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption by Major Countries from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption Share by Major Countries from 2014 to 2026

    • Figure Denmark B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Volume and Growth Rate from 2014 to 2026

    • Figure Finland B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Volume and Growth Rate from 2014 to 2026

    • Figure Norway B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Volume and Growth Rate from 2014 to 2026

    • Figure Sweden B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Volume and Growth Rate from 2014 to 2026

    • Figure Iceland B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Volume and Growth Rate from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption Share by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption Share by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption by Major Countries from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption Share by Major Countries from 2014 to 2026

    • Figure Belgium B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Volume and Growth Rate from 2014 to 2026

    • Figure Netherlands B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Volume and Growth Rate from 2014 to 2026

    • Figure Luxembourg B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Volume and Growth Rate from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption Share by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption Share by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption by Major Countries from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption Share by Major Countries from 2014 to 2026

    • Figure Estonia B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Volume and Growth Rate from 2014 to 2026

    • Figure Latvia B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Volume and Growth Rate from 2014 to 2026

    • Figure Lithuania Countries B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Volume and Growth Rate from 2014 to 2026

    • Table Company Profile and Development Status of Credit Suisse Securities

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Credit Suisse Securities

    • Figure Sales and Growth Rate Analysis of Credit Suisse Securities

    • Figure Revenue and Market Share Analysis of Credit Suisse Securities

    • Table Product and Service Introduction of Credit Suisse Securities

    • Table Company Profile and Development Status of Malin Corporation

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Malin Corporation

    • Figure Sales and Growth Rate Analysis of Malin Corporation

    • Figure Revenue and Market Share Analysis of Malin Corporation

    • Table Product and Service Introduction of Malin Corporation

    • Table Company Profile and Development Status of Sutro Biopharma

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Sutro Biopharma

    • Figure Sales and Growth Rate Analysis of Sutro Biopharma

    • Figure Revenue and Market Share Analysis of Sutro Biopharma

    • Table Product and Service Introduction of Sutro Biopharma

    • Table Company Profile and Development Status of Juno Therapeutics

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Juno Therapeutics

    • Figure Sales and Growth Rate Analysis of Juno Therapeutics

    • Figure Revenue and Market Share Analysis of Juno Therapeutics

    • Table Product and Service Introduction of Juno Therapeutics

    • Table Company Profile and Development Status of Deerfield Partners

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Deerfield Partners

    • Figure Sales and Growth Rate Analysis of Deerfield Partners

    • Figure Revenue and Market Share Analysis of Deerfield Partners

    • Table Product and Service Introduction of Deerfield Partners

    • Table Company Profile and Development Status of Onyx Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Onyx Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Onyx Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Onyx Pharmaceuticals

    • Table Product and Service Introduction of Onyx Pharmaceuticals

    • Table Company Profile and Development Status of Eureka Therapeutics

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Eureka Therapeutics

    • Figure Sales and Growth Rate Analysis of Eureka Therapeutics

    • Figure Revenue and Market Share Analysis of Eureka Therapeutics

    • Table Product and Service Introduction of Eureka Therapeutics

    • Table Company Profile and Development Status of Transposagen Biopharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Transposagen Biopharmaceuticals

    • Figure Sales and Growth Rate Analysis of Transposagen Biopharmaceuticals

    • Figure Revenue and Market Share Analysis of Transposagen Biopharmaceuticals

    • Table Product and Service Introduction of Transposagen Biopharmaceuticals

    • Table Company Profile and Development Status of Dana-Farber Cancer Institute

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Dana-Farber Cancer Institute

    • Figure Sales and Growth Rate Analysis of Dana-Farber Cancer Institute

    • Figure Revenue and Market Share Analysis of Dana-Farber Cancer Institute

    • Table Product and Service Introduction of Dana-Farber Cancer Institute

    • Table Company Profile and Development Status of Five Prime Therapeutics

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Five Prime Therapeutics

    • Figure Sales and Growth Rate Analysis of Five Prime Therapeutics

    • Figure Revenue and Market Share Analysis of Five Prime Therapeutics

    • Table Product and Service Introduction of Five Prime Therapeutics

    • Table Company Profile and Development Status of firstVentury Equity

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of firstVentury Equity

    • Figure Sales and Growth Rate Analysis of firstVentury Equity

    • Figure Revenue and Market Share Analysis of firstVentury Equity

    • Table Product and Service Introduction of firstVentury Equity

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US